Cognition Therapeutics, Inc. announced that its Phase 2 'START' Study of zervimesine (CT1812) in early Alzheimer's disease has reached the 75% enrollment mark. The study is designed to enroll approximately 540 individuals with mild cognitive impairment (MCI) and early Alzheimer’s disease.
The START Study is being conducted in collaboration with the Alzheimer’s Clinical Trials Consortium (ACTC) and is supported by an $81 million grant from the National Institute on Aging (NIA) at the National Institutes of Health. This strong enrollment pace is attributed to patient and investigator interest in a convenient, once-daily oral medication.
This milestone signifies continued operational progress in a key clinical trial, building on previous results from the SHINE Study that showed zervimesine slows cognitive deterioration in patients with lower levels of p-tau217. The company aims to further understand zervimesine’s potential across the Alzheimer’s spectrum.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.